Focus:
Comment
-
10 July 2020
ACE inhibitors, ARBs kindle interest to repurpose for Covid-19; potential risk apparent
by Manasi Vaidya in New York. Despite it being implicated in Covid-19, there is still equipoise on the role of angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis, there is a...
-
10 July 2020
Increased visibility into patient-reported outcomes during clinical trials through FDA initiative: Project Patient Voice
On 23 June, the FDA, in collaboration with its Oncology Center of Excellence, launched an initiative, Project Patient Voice, designed to advance development and regulation of oncology products and improve...
-
9 July 2020
Clinical trial disruption due to Covid-19 has begun to decline
Since early March, around 1,000 organisations supporting clinical trials as the sponsor, collaborator, or contract research organisation (CRO) have publically announced disruptions to planned and ongoing clinical trials in their...
-
2 July 2020
Trials Delayed Due to Covid-19 Begin to Resume
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the COVID-19 pandemic.
-
2 July 2020
FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors
by Reynald Castaneda in London, with additional reporting by Jennifer C Smith The FDA’s revocation of chloroquine and hydroxychloroquine's Emergency Use Authorization (EUA) after three months could mean the FDA...
-
26 June 2020
Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients
On 22 June, Gilead announced that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, and is hoping to extend further studies in patients with Covid-19...
-
25 June 2020
Dexamethasone, an unexpected drug, shows promise in treating Covid-19
Currently, there are over 2,200 clinical trials trying to find a vaccine or a therapy for Covid-19. The National Institute of Health recently halted its hydroxychloroquine clinical trial, concluding that...
-
23 June 2020
CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster
by Reynald Castaneda in London. Despite its advantages over other vaccine technologies for Covid-19, adenovirus vector vaccines are likely to be tripped up by pre-existing antibodies to the vectors used...
-
18 June 2020
The UK leads Covid-19 clinical investigations in Europe
As Europe has been significantly impacted by the Covid-19 pandemic, a substantial amount of clinical research is currently focused on identifying effective therapies and vaccines. GlobalData analysed the Covid-19 clinical...
-
18 June 2020
Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive
by Reynald Castaneda in London. Myovant Sciences’ Phase III relugolix trial in castrate-sensitive prostate cancer reporting of a positive trend in reducing major cardiovascular (CV) issues drew mostly expert scepticism. The...